NICE has developed a medtech innovation briefing (MIB) on EarlySense for heart and respiratory monitoring and predicting patient deterioration.

The EarlySense system, using the Vitals software option, is used to continuously monitor heart rate and respiratory rate for patients in hospital. A sensor placed under the mattress continuously collects data while the patient is in bed and the system alerts healthcare professionals if rates change, indicating patient deterioration. Validation studies suggest that the EarlySense system records heart and respiratory rate accurately, and that its alerts are predictive of clinical deterioration. One non randomised comparative study reported reduced length of stay and fewer intensive care transfers compared with standard monitoring. The system, together with the Vitals software option, costs about £35,000 for a 10 bed unit and the sensor must be replaced annually at a cost of £475.00 per bed (excluding VAT).

MIBs provide a description of the medical technology, including its likely place in therapy, the costs of using the technology and a critical review of the strengths and weaknesses of the relevant published evidence.

Their purpose is to provide objective information on device and diagnostic technologies to aid local decision-making by clinicians, managers and procurement professionals. By making this information available, NICE helps to avoid the need for NHS organisations to produce similar information for local use.

MIBs are not NICE guidance. They differ in format, contain no judgement on the value of the technology and do not constitute a guidance recommendation.

MIBs are commissioned by NHS England and produced in support of the NHS 5 Year Forward View, specifically as one of a number of steps which will accelerate innovation in new treatments and diagnostics.